The estimated Net Worth of Paul Biondi is at least $6.74 Thousand dollars as of 2 October 2019. Mr. Biondi owns over 592 units of Seres Therapeutics Inc stock worth over $6,738 and over the last 6 years he sold MCRB stock worth over $0. In addition, he makes $0 as Independent Director at Seres Therapeutics Inc.
Paul has made over 4 trades of the Seres Therapeutics Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he exercised 592 units of MCRB stock worth $622 on 2 October 2019.
The largest trade he's ever made was exercising 8,619 units of Seres Therapeutics Inc stock on 10 March 2019 worth over $9,050. On average, Paul trades about 1,024 units every 42 days since 2018. As of 2 October 2019 he still owns at least 6,417 units of Seres Therapeutics Inc stock.
You can see the complete history of Mr. Biondi stock trades at the bottom of the page.
Paul R. Biondi serves as Independent Director of the Company. Mr. Biondi is an Executive Partner at Flagship Pioneering where he has been since November 2019. Mr. Biondi joined Flagship Pioneering following a seventeen-year tenure at Bristol-Myers Squibb (“BMS”), a pharmaceutical company, where he was most recently the Senior Vice President of Strategy and Business Development. Prior to serving in the role of Senior Vice President of Strategy, from 2002 to 2015, Mr. Biondi held a series of other leadership roles within BMS’ Research and Development organization overseeing strategy, portfolio and project management, as well as clinical and business operations. Mr. Biondi holds a bachelor’s degree from Dartmouth College and an M.B.A. from the J.L. Kellogg School of Management at Northwestern University.
Paul Biondi is 51, he's been the Independent Director of Seres Therapeutics Inc since 2020. There are 13 older and 7 younger executives at Seres Therapeutics Inc. The oldest executive at Seres Therapeutics Inc is Dennis Ausiello, 74, who is the Independent Director.
Paul's mailing address filed with the SEC is C/O SERES THERAPEUTICS, INC., 101 CAMBRIDGE PARK DRIVE, CAMBRIDGE, MA, 02140.
Over the last 9 years, insiders at Seres Therapeutics Inc have traded over $37,132,594 worth of Seres Therapeutics Inc stock and bought 17,627,131 units worth $47,525,463 . The most active insiders traders include Noubar Afeyan, Health Ltp Fund General Par..., and Health Science Us Holdings,.... On average, Seres Therapeutics Inc executives and independent directors trade stock every 35 days with the average trade being worth of $251,393. The most recent stock trade was executed by Thomas Des Rosier on 15 August 2024, trading 2,656 units of MCRB stock currently worth $2,789.
seres therapeutics is a clinical stage biotherapeutic company focused on discovering and developing ecobiotic™ therapeutic products, novel drugs to treat important diseases by targeting the underlying biology of the human microbiome. founded by flagship venturelabs, seres is pioneering the first therapeutics that catalyze a shift to health by augmenting the biology of the microbiome. current candidates span infectious, metabolic, and inflammatory diseases. for more information, please visit http://serestherapeutics.com/.
Seres Therapeutics Inc executives and other stock owners filed with the SEC include: